These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 31166523)

  • 21. [Incidence of strokes in HIV-positive patients treated with long term antiretroviral treatment].
    Mapoure YN; Nkongni IN; Luma HN; Ngahane BH; Barla E; Ngwane S; Mouelle AS; Njamnshi AK
    Pan Afr Med J; 2016; 24():45. PubMed ID: 27642386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular complications in HIV management: past, present, and future.
    Aberg JA
    J Acquir Immune Defic Syndr; 2009 Jan; 50(1):54-64. PubMed ID: 19295335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Patients living with human immunodeficiency virus on antiretroviral therapy diagnosed with lipid and carbohydrate disorders who are at risk of cardio-vascular disease: study conducted at the Medical Centre of the ONG Espoir Vie in Lomé].
    Agbeko DK; Toyi T; Lihanimpo D; Dzidzonu NK; Laconi K; Abago B; Awalou DM
    Pan Afr Med J; 2019; 34():203. PubMed ID: 32180877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
    AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
    Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
    BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir).
    Domingos H; da Cunha RV; Paniago AM
    Braz J Infect Dis; 2007 Apr; 11(2):290-2. PubMed ID: 17625780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
    J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso).
    Guira O; Tiéno H; Diendéré AE; Sagna Y; Diallo I; Yaméogo B; Zoungrana L; Yaméogo TM; Bognounou R; Drabo JY
    J Int Assoc Provid AIDS Care; 2016; 15(2):159-63. PubMed ID: 26307211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.
    Davidson I; Beardsell H; Smith B; Mandalia S; Bower M; Gazzard B; Nelson M; Stebbing J
    Antiviral Res; 2010 May; 86(2):227-9. PubMed ID: 20211651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Increased cardiovascular risk in HIV patients].
    Wierema TK
    Ned Tijdschr Geneeskd; 2010; 154():A788. PubMed ID: 20456808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of HAART in patients treated during acute HIV infection.
    Vlassi C; Corpolongo A; D'Offizi G; Scognamiglio P; Salvatori MF; Fezza R; Narciso P
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):e11-2. PubMed ID: 20647820
    [No Abstract]   [Full Text] [Related]  

  • 37. Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.
    Gagliardini R; Fabbiani M; Colafigli M; D'Avino A; Mondi A; Borghetti A; Lamonica S; Cauda R; De Luca A; Di Giambenedetto S
    J Chemother; 2017 Oct; 29(5):299-307. PubMed ID: 28019192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.
    Magenta L; Dell-Kuster S; Richter WO; Young J; Hasse B; Flepp M; Hirschel B; Vernazza P; Evison J; Cavassini M; Decosterd LA; Bucher HC; Bernasconi E;
    AIDS Res Hum Retroviruses; 2011 May; 27(5):525-33. PubMed ID: 20854107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
    BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.